Platelet-derived growth factor receptor inhibition reduces allograft arteriosclerosis of heart and aorta in cholesterol-fed rabbits

Transplantation

Volumn 75, Issue 3, 2003, Pages 334-339

  Sihvola, Roope K ^a   Tikkanen, Jussi M ^a   Krebs, Rainer ^a   Aaltola, Eva M ^a   Buchdunger, Elisabeth ^b   Laitinen, Outi ^a   Koskinen, Petri K ^a,c   Lemström, Karl B ^a,c  

^a UNIVERSITY OF HELSINKI   (Finland)

^b NOVARTIS PHARMA AG   (Switzerland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; DRUG VEHICLE; IMATINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; SC 9974;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTERIOSCLEROSIS; ARTERY DIAMETER; ARTERY INTIMA PROLIFERATION; ARTERY LESION; ARTERY OCCLUSION; ARTICLE; ASCENDING AORTA; CELL PROLIFERATION; CHOLESTEROL DIET; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECT; FEMALE; GRAFT REJECTION; HEART GRAFT; HEART TRANSPLANTATION; HETEROTOPIC TRANSPLANTATION; HYPERCHOLESTEROLEMIA; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; MORBIDITY; NONHUMAN; PRIORITY JOURNAL; RABBIT; SMOOTH MUSCLE FIBER; STATISTICAL ANALYSIS;

ANIMALS; ANTINEOPLASTIC AGENTS; AORTA, THORACIC; AORTIC DISEASES; CHOLESTEROL, DIETARY; CORONARY ARTERIOSCLEROSIS; FEMALE; GRAFT SURVIVAL; HEART TRANSPLANTATION; HYPERCHOLESTEROLEMIA; INCIDENCE; MACROPHAGES; PIPERAZINES; PLATELET-DERIVED GROWTH FACTOR; PYRIMIDINES; RABBITS; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; TRANSPLANTATION, HOMOLOGOUS;

EID: 0037442167     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000045056.82561.0F     Document Type: Article

References (22)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362(6423): 801.
2. Tullius SG, Tilney NL. Both alloantigen-dependent and independent factors influence chronic allograft rejection. Transplantation 1995; 59(3): 313.
3. Kobashigawa JA, Kasiske BL. Hyperlipidemia in solid organ transplantation. Transplantation 1997; 63(3): 331.
4. Alonso DR, Starek PK, Minick CR. Studies on the pathogenesis of atheroarteriosclerosis induced in rabbit cardiac allografts by the synergy of graft rejection and hypercholesterolemia. Am J Pathol 1977; 87(2): 415.
5. Lemström KB, Koskinen PK. Expression and localization of platelet-derived growth factor ligand and receptor protein during acute and chronic rejection of rat cardiac allografts. Circulation 1997; 96(4): 1240.
6. Sihvola R, Koskinen P, Myllarniemi M, et al. Prevention of cardiac allograft arteriosclerosis by protein tyrosine kinase inhibitor selective for platelet-derived growth factor receptor. Circulation 1999; 99(17): 2295.
7. Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl proteintyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996; 56(1): 100.
8. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295(1): 139.
9. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344(14): 1031.
10. Myllärniemi M, Frösen J, Calderon Ramirez LG, et al. Selective tyrosine kinase inhibitor for the platelet-derived growth factor receptor in vitro inhibits smooth muscle cell proliferation after reinjury of arterial intima in vivo. Cardiovasc Drugs Ther 1999; 13(2): 159.
11. Valantine HA, Schroeder JS. HMG-CoA reductase inhibitors reduce transplant coronary artery disease and mortality: evidence for antigen-independent mechanisms? Circulation 1997; 96(5): 1370.
12. McManus BM, Horley KJ, Wilson JE, et al. Prominence of coronary arterial wall lipids in human heart allografts. Implications for pathogenesis of allograft arteriopathy. Am J Pathol 1995; 147(2): 293.
13. Ross R, Raines EW, Bowen-Pope DF. The biology of platelet-derived growth factor. Cell 1986; 46(2): 155.
14. Ross R, Masuda J, Raines EW, et al. Localization of PDGF-B protein in macrophages in all phases of atherogenesis. Science 1990; 248(4958): 1009.
15. Lamb DJ, Avades TY, Ferns GA. Endogenous neutralizing antibodies against platelet-derived growth factor-aa inhibit atherogenesis in the cholesterol-fed rabbit. Arterioscler Thromb Vasc Biol 2001; 21(6): 997.
16. Sano H, Sudo T, Yokode M, et al. Functional blockade of platelet-derived growth factor receptor-beta but not of receptor-alpha prevents vascular smooth muscle cell accumulation in fibrous cap lesions in apolipoprotein E-deficient mice. Circulation 2001; 103(24): 2955.
17. Billett MA, Adbeish IS, Alrokayan SA, et al. Increased expression of genes for platelet-derived growth factor in circulating mononuclear cells of hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 1996; 16(3): 399.
18. Bath PM, Martin JF. Serum platelet-derived growth factor and endothelin concentrations in human hypercholesterolaemia. J Int Med 1991; 230(4): 313.
19. Sihvola RK, Pulkkinen VP, Koskinen PK, et al. Crosstalk of endothelin-1 and platelet-derived growth factor in cardiac allograft arteriosclerosis. J Am Coll Cardiol 2002; 39(4): 710.
20. Koskinen PK, Häyry JH, Lemström, KB. How cyclosporine modifies histological and molecular events in the vascular wall during chronic rejection of rat cardiac allografts. Am J Pathol 1995; 146(4): 972.
21. Stoltenberg RL, Geraghty J, Steele DM, et al. Inhibition of intimal hyperplasia in rat aortic allografts with cyclosporine. Transplantation 1995; 60(9): 993.
22. Richter M, Skupin M, Schramm D, et al. Cyclosporine does not enhance the development of accelerated coronary artery disease: experimental study in a rat cardiac transplant model. J Heart Lung Transplant 2002; 21(4): 425.